



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



LETTER TO THE EDITOR

Pulmonary toxicity by oxygen and COVID-19[☆]



Toxicidad pulmonar por oxígeno y COVID-19

To the Editor,

Pulmonary toxicity by oxygen has been known for over a century. Exposure to a fraction of inspired oxygen (FiO₂) of 0.7 causes progressive pulmonary lesion and the intensity of the lesions is associated with the concentration and duration of hyperoxia.¹ Lesion manifests just a few hours after the administration of oxygen in high concentrations causing an increased alveolar-capillary patency and a complex cellular response including epithelial, endothelial, proinflammatory cells, and platelets that induce the destruction of alveolocapillary membranes with increased air spaces, vascular obstruction due to microthrombi, and cellular infiltration that eventually leads to the loss of alveolar architecture and, in the long run, to pulmonary fibrosis. All oxygen-induced lesions are similar to those due to acute respiratory distress syndrome (ARDS). Also, in patients with established ARDS, hyperoxia can worsen clinical results.² Finally, many of the pathological characteristics reported in hyperoxia occur also in ARDS due to COVID-19 since it has been reported that in these patients' lungs increased air spaces following the destruction of alveolar septa, alveolar swelling, capillary thrombosis, perivascular infiltrates, and fibrosis have been found.³

The appearance of COVID-19 has challenged respiratory support, and the need for applying elevated fractions of inspired oxygen has been a constant in many patients whether through high-flow nasal oxygen (HFNO) therapy or concomitantly to ventilation systems. However, the high mortality rates reported in cases of ARDS—an average of 39%—is indicative that, at least in some cases, the application of elevated concentrations of oxygen is worsening or triggering COVID-19³-related ARDS-like lesions. It could even cause a vicious circle that would create the need to increase the concentration of oxygen gradually in the air breathed in thus causing greater pulmonary impairment.

This possibility—together with data obtained by other authors⁴ that most patients with moderate-to-severe acute

respiratory failure due to COVID-19, and even cases with radiological findings and compatible gas exchange with ARDS recovered with CPAP and FiO₂ between 0.4 and 0.6, should, in own opinion, make us reconsider or detail the current strategy of respiratory support. Therefore, following the plan established by current recommendations,⁵ although the next step towards conventional oxygen therapy can still be HFNO when FiO₂ > 0.6 would be needed respiratory support like CPAP should be attempted to recruit more alveolar units before increasing FiO₂ to levels that can be toxic to an already damaged lung. Even under certain safety and monitoring conditions, the saturation target currently established at around 95% in the aforementioned current recommendations could be reduced down to 92% to stop FiO₂ from going > 0.6.

References

1. Kallet RH, Branson RD. Should Oxygen Therapy Be Tightly Regulated to Minimize Hyperoxia in Critically Ill Patients? *Respir Care*. 2016;61:801–17.
2. Aggarwal NR, Brower RG, Hager DN, Thompson BT, Netzer G, Shanholtz C, et al. Oxygen exposure resulting in arterial oxygen tensions above the protocol goal was associated with worse clinical outcomes in acute respiratory distress syndrome. *Crit Care Med*. 2018;46:517–24.
3. Hanidziar D, Robson SC. Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19. *Am J Physiol Lung Cell Mol Physiol*. 2021;320:L12–6.
4. Brusasco C, Corradi F, di Domenico A, Raggi F, Timossi G, Santori G, et al., Galliera CPAP-Covid-19 study group; Collaborators of the Galliera CPAP-COVID-19 study group are. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure. *Eur Respir J*. 2021;57:2002524.
5. Belenguer-Muncharaz A, Hernández-Garcés H. Indication of high-flow oxygen therapy in patients with SARS-CoV-2 pneumonia. *Med Intensiva*. 2020, <http://dx.doi.org/10.1016/j.medint.2020.11.001>. S0210-5691(20)30340-5.

A. León-Jiménez, E. Vázquez-Gandullo*,
F. Montoro-Ballesteros
Unidad de Gestión Clínica de Neumología, Alergología y Cirugía Torácica, Servicio de Neumología, Hospital Universitario Puerta del Mar, Cádiz, Spain

* Corresponding author.

E-mail address: evavgandullo@gmail.com
(E. Vázquez-Gandullo).

[☆] Please cite this article as: León-Jiménez A, Vázquez-Gandullo E, Montoro-Ballesteros F. Toxicidad pulmonar por oxígeno y COVID-19. *Med Intensiva*. 2022;46:353.